Clinical Trial Update: Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma [Phase 1, Phase 2]

View source ↗

Summary

The document reports ongoing recruitment for a phase 1/phase 2 trial evaluating intradermal ipilimumab plus nivolumab in high-risk stage II melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Ipilimumab (Yervoy) (ipilimumab)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Melanoma | Phase 1, Phase 2 | Status: RECRUITING